Brandon Cieniewicz, PhD profile page

Brandon Cieniewicz, Ph.D., is Director, Research & Development at CERo Therapeutics, where he leads the advancement of the company’s CER-T cell therapy platform from discovery research through clinical translation. He joined CERo in 2020 following a postdoctoral fellowship at Stanford Medicine in the Roncarolo Lab, where his research focused on type 1 regulatory T cell interactions in acute myeloid leukemia (AML). He earned his Ph.D. in Molecular and Cellular Biology from Stony Brook University and holds a B.S. from the University of Richmond. With deep expertise in immunology and oncology, Brandon has played a central role in developing CERo’s engineered cell therapy approach and advancing it into clinical-stage development, bridging fundamental immune biology with next-generation therapeutic design.